Complement and microglia mediate early synapse loss in Alzheimer mouse models
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Abstract
Too much cleaning up: The complement system and microglia seek out and destroy unwanted cellular debris for the peripheral immune system as well as excess synapses in the developing brain. Hong et al. now show how the system may go haywire in adults early in the progression toward Alzheimer's disease (AD). Aberrant synapse loss is an early feature of Alzheimer's and correlates with cognitive decline. In mice susceptible to AD, complement was associated with synapses, and microglial function was required for synapse loss. The authors speculate that aberrant activation of this “trash disposal” system underlies AD pathology. Science , this issue p. 712
Overview
CoChat Summary
TL;DR
In Alzheimer mouse models, classical complement proteins C1q and C3 increase and localize to synapses before plaques, and blocking C1q, C3, or microglial CR3 reduces early synapse loss. Soluble Aβ oligomers drive microglial engulfment of synaptic material through a CR3-dependent pathway, suggesting reactivation of developmental synaptic pruning in early AD.
Key findings
- J20 hAPP mice showed significant hippocampal synapse loss at 3–4 months, before plaque deposition; loss occurred in CA1, CA3, and dentate gyrus at 3 months but not in striatum, and was not seen at 1 month.
- C1q was elevated in J20 brains as early as 1 month, region-specifically in hippocampus and frontal cortex, and colocalized with PSD95-positive puncta; Compound E reduced soluble Aβ and C1q deposition, while oligomeric Aβ—but not monomeric Aβ or vehicle—induced C1q deposition and synaptic colocalization.
- Oligomeric Aβ induced synapse loss within 72 h in WT mice but not in C1qa knockout mice; anti-C1q antibody ANX-M1 prevented oAβ-induced synapse loss and LTP impairment, and APP/PS1xC3 KO mice did not show the synapse loss seen in 4-month APP/PS1 hippocampus.
- Microglial CD68 increased in J20 hippocampus and after oAβ; oAβ increased internalized Homer-GFP in microglia, failed to do so in CR3 KO mice, and induced hippocampal synapse loss in WT but not CR3 KO mice.
Methods
- Mouse models included J20 hAPP, APP/PS1, C1qa KO, C3 KO, CR3 KO, and Homer-GFP mice, with WT littermates and ages including 1 month, 3–4 months, and P21.
- Synapse quantification used super-resolution structured illumination microscopy, confocal imaging, and electron microscopy with colocalized pre- and postsynaptic puncta markers including synaptophysin/PSD95, synaptotagmin/homer, and synapsin/PSD95; C1q and C3 colocalization with PSD95 was also measured.
- Interventions included Compound E, intracerebroventricular or tail vein injections of soluble Aβ oligomers, monomers, or vehicle, anti-C1q antibody ANX-M1 or IgG control, acute hippocampal slice LTP recordings, and an in vivo synaptic engulfment assay.
Limitations
- The paper states that specific synaptic C1q receptors are not yet known and that oAβ and C1q may act indirectly through cytokines such as TGFβ, microglial or astrocytic activation, or other pathways including MHCI/PirB.
- The paper states that the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, and that future studies are needed to examine plaque-associated synapse loss and other synaptopathies such as tauopathies and Huntington’s disease.
- Evident from the text: the findings are from mouse models and acute hippocampal slices, not human AD tissue or clinical trials, and the study focuses on early pre-plaque mechanisms rather than established plaque-associated neuropathology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [5] Stevens B The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 1164 1178 18083105 source
The Results report C1q localized to synapses in the developing dLGN during synaptic pruning and relocalized to adult retinal synapses in early glaucoma, before significant synapse loss. The Discussion likewise places synaptic C1q relocalization before or concurrent with synapse loss in the glaucoma model. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [27] Stephan AH Barres BA Stevens B The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci 2012 35 369 389 22715882 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to developmental synaptic pruning (6).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [6] Schafer DP Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 2012 74 691 705 22632727 PMC3528177 source
The Results section, “Microglia engulf RGC inputs during a period of active synaptic pruning” (page unavailable), reports that most engulfed RGC inputs colocalized with microglial lysosomal compartments. The Results section, “Microglia engulf presynaptic elements specific to RGCs” (page unavailable), also identifies an RGC presynaptic marker within microglial lysosomes, supporting the proposed similarity to developmental synaptic pruning. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Quantification of colocalized pre- and postsynaptic puncta (synaptophysin and PSD95 (Fig. 1A); synaptotagmin and homer (figs. S1A-D)) revealed a significant loss of synapses in J20 hippocampus at 3-4 months old (mo), an age that precedes plaque deposition (11, 12).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [11] Mucke L High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience 2000 20 4050 10818140 PMC6772621 source
The citation is attached to the statement that 3–4 months precedes plaque deposition, not to the citing authors’ synapse measurements. In “Effects of hAPP mutations on formation of amyloid plaques” (Fig. 4; page not provided), the paper assesses mice at 2–4 months and reports amyloid deposition in APP Sw,Ind mice at 5–7 months; the paper identifies J20 as an APP Sw,Ind line. (LLM, conf=0.91)
- Supportedcites [12] Hong S Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience 2011 31 15861 15869 22049429 PMC3227224 source
The citation follows the statement that 3–4 months precedes plaque deposition, rather than the citing authors’ own synapse measurements. The Results section (page unavailable) identifies approximately 3-month-old J20 mice as pre-plaque and describes 3–7-month-old mice as plaque-free. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genome-wide association studies (GWAS) implicate microglia and complement-related pathways in AD (1).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [1] Hong S Dissing-Olesen L Stevens B New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 2016 doi:10.1016/j.conb.2015.12.004 PMC5479435 26745839 source
The Introduction says GWAS and integrated network studies identify immune-related AD risk pathways implicating microglia. The section on microglia–synapse dysfunction identifies GWAS variants CLU and CR1, both related to complement. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“C1q was also similarly increased in hippocampus of another model of AD, the APP/PS1 mice (15) (Fig. S2C).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [15] Jankowsky JL Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet 2004 13 159 170 14645205 source
The citation identifies the APP/PS1 mouse model, while the citing document points to its own Fig. S2C for the C1q increase. Figure 2 (p. 4) describes APPswe/PS1 double-transgenic mice and shows hippocampal amyloid pathology in that model. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 5 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurodegeneration, the complement pathway is activated, and inhibiting the complement proteins C1q or C3 results in less neuroinflammation, Aβ plaques and synapse loss29,30.”
From Exercise plasma boosts memory and dampens brain inflammation via clusterin (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before the onset of Aβ deposition, microglia engulf synapses opsonized with the complement factors C1q and C3 upon CR3-mediated recognition of C3 (121).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of C1q, C3, or CR3 curbed microglia activation and synaptic loss during amyloid plaque deposition.”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [139]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inappropriate control of the classical complement cascade causes unresolvable inflammation and disease (Hong et al. , 2016; Hansen, Hanson and Sheng, 2018; Morgan, 2018).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Hong et al., 2016
Experimental — accuracy not yet measured
70 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Cited work 10.1038/nn.3560 · retracted 2022-01-13 · notice 10.1038/s41593-021-00877-7 · this paper published 2016-05-06
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 2×
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synaptic deficits occur in early AD and mild cognitively impaired patients before onset of plaques and are some of the first signs of the neuronal degenerative process (4, 23-25).”
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 4×
“Although specific receptors for C1q at synapses are not yet known, C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
InfluentialSelf-citationIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“S11), indicating they are resident cells (22).”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 3×
“S4), long before Aβ plaques deposit (11, 12), raising the question of whether C1q increase in these pre-plaque brains is dependent on soluble Aβ levels.”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Cited by
Items 2,301–2,400 of 3,349
Barclay, K. M., Abduljawad, N., Cheng, Z., Kim, M. W., Zhou, L., Jin, Y., Rustenhoven, J., Mazzitelli, J. A., Smyth, L. C. D., Beatty, W. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.01.569597 · Cited by 5
Extracellular matrix and microglial regulation of cognitive agingPreprint
Gray, D. T., Gutierrez, A., Jami‐Alahmadi, Y., Pandey, V., Pan, L., Zhang, Y., Wohlschlegel, J. A., McDevitt, R. A., & Biase, L. M. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574215 · Cited by 5
Paoli‐Iseppi, R. D., Joshi, S. S., Gleeson, J., Prawer, Y. D. J., You, Y., Agarwal, R., Li, A., Hull, A., Whitehead, E. M., Seo, Y., et al. (2024) · medRxiv · doi:10.1101/2024.02.22.24303189 · Cited by 5
LRRK2 regulates synaptic function through BDNF signaling and actin cytoskeletonPreprint
Tombesi, G., Kompella, S. N., Favetta, G., Chen, C., Zhao, Y., Sevegnani, M., Marte, A., Battisti, I., Morosin, E., Ornaghi, M., et al. (2024) · eLife · doi:10.7554/elife.95987.1 · Cited by 6
Bergendorf, A. M., Park, J. H., Ball, B. K., & Brubaker, D. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.07.637100 · Cited by 5
“In addition, Aβ promotes cognitive dysfunction by increasing the number of synapses removed by microglia through the complement system (12).”
de Rezende, V. L., da Costa, M. D. A., Martins, C. D., Mathias, K., Gonçalves, C. L., Barichello, T., & Petronilho, F. C. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04361-7 · Cited by 7
“In the brain, aging is accompanied by a series of cellular and functional impairments, such as pro-inflammatory changes and the accumulation of complement system factors in microglia [61, 107] that collectively drive vulnerability to neurological disorders.”
Johnson, B. J., Andrews, R. N., Olson, J. D., & Cline, J. M. (2025) · Radiation Research · doi:10.1667/rade-24-00033.1 · Cited by 5
Zhang, Y., Liu, X., Gao, Y. H., Fu, C., Xue, Y., Wang, D., Hong, J., Ren, L., Zha, L.-W., Ling, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115284 · Cited by 4
Rationale and emerging evidence for microglial replacement in Alzheimer’s disease
Bang, J. Y., & Yoo, Y. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100265 · Cited by 8
Fu, W., Guo, Y., Wu, P., Xiao, L., Qi, W., Cao, H., Dong, N., Zhao, R. C., & Wang, J. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106082 · Cited by 5
Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer’s disease brain
Carnevale, L. N., Banerjee, P., Zhang, X., Navarro, J., Raspur, C. K., Patel, P. R., Nakamura, T., Schahrer, E., Scott, H. R., Lang, N., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.03.017 · Cited by 6
Zhao, X., & He, Z. (2025) · Neuroscience Research · doi:10.1016/j.neures.2025.104979 · Cited by 5
Zhang, Y., Watson, B. R., Rattan, A., Lee, T., Chawla, S., Geistlinger, L., Guan, Y., Lord, F. B., Ma, M., Miwa, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66048-5 · Cited by 10
Gao, C., Lin, Z., Chen, Y., Gan, R., Wang, K., He, X., & Han, H. (2025) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0015 · Cited by 8
“Furthermore, chronically activated microglia contribute to cognitive decline via excessive or aberrant synaptic pruning [41].”
Unmasking early microglial remodeling in an Alzheimer’s disease mouse model
Saminathan, P., McArdle, S., Corey, M., Nadig, N., Fang, C., Gibbons, A., Rayadurgam, M., & Sharma, S. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1720382 · Cited by 3
“Microglial complement signaling then drives early synapse elimination and memory deficits, while blockade of complement protects synapses and neurocognitive behavior (Hong et al., 2016; Shi et al., 2017).”
InfluentialSalminen, A. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106115 · Cited by 5
Advances in research on the complement system and cognitive impairment
Gao, J., Li, Z., Zhang, X., Huang, W., Tian, Z., Xiao, C., Zhen, Y., Yu, F., & Cao, X. (2026) · Immunobiology · doi:10.1016/j.imbio.2026.153157 · Cited by 4
The axon initial segment-associated microglia regulate neuronal activity and visual perception
Wang, Y., Wang, Q., Gao, C., He, S., Wei, C., Song, J., Liu, X., Liu, X., Feng, S., Yao, W., et al. (2026) · Cell Research · doi:10.1038/s41422-026-01218-8 · Cited by 4
“20 A recent study also suggests that MGs can form specialized purinergic junctions with neuronal somata to protect against hyperexcitation or excitotoxicity in neurodegenerative disorders such as stroke.”
Gao, M., Zhou, J., Shi, N., Yan, X., & Liang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1742677 · Cited by 6
“Complement activation cleaves C3 and C5, generating C3b and iC3b, which deposit on target cell surfaces as opsonins for CR3 recognition by microglia (69).”
Liu, R., Deng, Q., Gong, L., & Yang, L. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01598-2 · Cited by 6
“…pathological changes, including Aβ accumulation or neuroinflammation in AD, can trigger the sustained activation of the classical complement cascade, leading to the upregulation of the classical complement system and the deposition of C3 products on the surface of mature synapses [98, 208, 210].”
InfluentialComplement and inflammasome crosstalk in chronic inflammation
Janžič, L., & Kouter, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778759 · Cited by 9
“This complement – in fl ammasome crosstalk creates a self-reinforcing in fl ammatory loop, as evidenced by improved pathology and cognition in NLRP3-or caspase-1-de fi cient AD mouse models (92, 93).”
Marcatti, M., Labastida, J. A., Tang, T. Z., Ahmad, A., Payne, C., Schwartz, N., Villarreal, P. P., Solomon, O. D., Vargas, G., Wu, P., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2527009123 · Cited by 7
“Dysfunctional neurons release signals that perpetuate microglial reactivity, while activated microglia alter neuronal excitability and synaptic plasticity through cytokine signaling, complement cascade activation, and aberrant synaptic pruning (9, 12).”
The dual role of microglia in neurodegenerative diseases: A review
Zhang, N., Xiong, N., He, Y., & Zhou, L. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111887 · Cited by 9
Liu, H., Hu, C., Liu, H., Gong, Z., Jiang, S., Xie, J., Li, Y., Liu, C., Wang, Y., Zou, C., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03815-1 · Cited by 10
“…associated with a shift of microglia toward IFN-enriched states (e.g., DAM/IFN-MG-like programs), characterized by upregulation of phagocytic receptors (Trem2, Axl), chemokines (Ccl2/Cxcl10), and complement components (C1q/C3), which together potentiate synaptic tagging and engulfment [74–76].”
Atypical chemokine receptor 3 regulates synaptic removal in disease astrocytes
Giusti, V., Park, J., Giusto, E., Masatti, L., Ramos‐Gonzalez, P., Iovino, L., Sandre, M., Emmi, A., Kaur, G., Coletto, E., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00976-8 · Cited by 8
Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
“Knockout of C1q rescued this phenotype, suggesting a necessary role of complement for the Aβ-mediated synapse loss [112].”
Discovery of plasma biomarkers related to blood-brain barrier dysregulation in Alzheimer’s disease
Dan, Y. R., & Chiam, K. (2024) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2024.1463001 · Cited by 5
Li, S., You, M., Chen, C., Fu, J., Xu, Y., Pi, J., & Wang, Y. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117620 · Cited by 9
Self-citationAlzheimer’s disease and diabetes-associated cognitive dysfunction: the microglia link?
Liu, Y., Li, T., & Xiong, J. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01516-3 · Cited by 4
“Microglia are known to become excessively activated in neurodegenerative diseases like AD and DACD, even before physical symptoms or brain imaging changes occur (Hong et al. 2016; Salter and Stevens 2017).”
Huang, S., Nunez, J., Toresco, D. L., Wen, C., Slotabec, L. A., Wang, H., Zhang, H., Rouhi, N., Adenawoola, M. I., & Li, J. (2025) · The FASEB Journal · doi:10.1096/fj.202402725rr · Cited by 8
“81 Additionally, other tau pathologies have been found to induce mitochondrial dysfunction and apoptosis, further driving neurodegeneration in AD.”
Zhang, P., Cheng, R.-J., Yang, Q., Gong, Y., Xu, Y., Chen, L., Zhou, L., & Jiang, C. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.02.008 · Cited by 5
Microglial phagocytosis and regulatory mechanisms: Key players in the pathophysiology of depression
Wang, M., Jin, G., Duan, T., Li, R., Gao, Y., Yu, M., & Xu, Y. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110383 · Cited by 8
Liu, K., Hong, J., Li, Y., Wang, Q., Dong, R., Liu, T., Guo, X., Chen, L., & Li, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114508 · Cited by 5
Kim, Y. D., Vaidya, B., McInnes, J., & Zoghbi, H. Y. (2025) · eNeuro · doi:10.1523/eneuro.0357-24.2025 · Cited by 3
“Astrogliosis (Liddelow et al., 2017; Chun and Lee, 2018; Zeng et al., 2020) and microglia activation (McGeer et al., 1988; Hong et al., 2016) are common features in PD and various other neurodegenerative diseases.”
Das, S., Devinney, M. J., Berger, M., & Brown, C. H. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.03.003 · Cited by 5
Chunchai, T., Pintana, H., Kunasol, C., Pantiya, P., Arunsak, B., Kerdphoo, S., Nawara, W., Donchada, S., Apaijai, N., Sripetchwandee, J., et al. (2025) · Acta Physiologica · doi:10.1111/apha.70060 · Cited by 6
“In addition, growing evidence demonstrated that the innate immune cells, including microglia, are capable of IIM [21, 22].”
InfluentialYang, Z. X., Sheng, J., Zhang, Q., Zhao, X., Song, Y., Dong, G., Zhang, R., Zhao, H., Wang, J., Pan, R., et al. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26584 · Cited by 7
“Microglial involvement in synaptic pruning and synaptic activity regulation also highlights the importance of these mechanisms for understanding the pathophysiology of AD [166,167].”
Yao, M., Liu, A., Song, J., Xing, L., Huang, Y., & Li, H. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149852 · Cited by 5
Xu, B., Bai, Y., Liu, Z., Li, J., Chen, K., Yan, Z., Wang, Y.-Y., Xu, J., Wang, H., Shi, F., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.001 · Cited by 4
Gollihue, J. L., Aung, K. Z., Rogers, C. B., Galopin, L. B., Wright, N. A., Sompol, P. M., Weekman, E. M., Katsumata, Y., Morganti, J. M., & Norris, C. M. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03523-2 · Cited by 8
C4d, a high-affinity LilrB2 ligand, is elevated in Alzheimer’s disease and mediates synapse pruning
Brott, B. K., Raissi, A. J., Micheva, K. D., Vielmetter, J., Mendes, M. S., Baccus, C. J., Huang, J., & Shatz, C. J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2519253122 · Cited by 7
Bello, E., Long, K. R., Iwama, S., Steer, J., Cooper, S., Alasoo, K., Kumasaka, N., Schwartzentruber, J., Panousis, N. I., & Bassett, A. R. (2026) · iScience · doi:10.1016/j.isci.2026.115688 · Cited by 7
“29 Moreover, sustained microglia activation appears to contribute to neurode-generation by impacting synaptic plasticity and causing neuronal damage.”
Ojiro, R., Watanabe, Y., Okano, H., Takahashi, Y., Takashima, K., Tang, Q., Ozawa, S., Saito, F., Akahori, Y., Jin, M., et al. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4263 · Cited by 5
“It has also been suggested that C3 is involved in the synaptic loss that occurs in mouse models of Alzheimer's disease (Hong et al., 2016).”
BackgroundXing, Y., Zhang, D., Fang, L., Wang, J., Liu, C., Wu, D., Liu, X., Wang, X., & Min, W. (2023) · Foods · doi:10.3390/foods12193580 · Cited by 4
“In contrast, blocking C1q activation using C1q knockdown or antibodies has been shown to significantly reduce synaptic phagocytosis and cognitive dysfunction [1].”
BackgroundInfluentialAnalysis of complement system and its related factors in Alzheimer’s disease
Zhu, X., Tang, B.-F., Zhu, M.-Z., Lu, J. N., Lin, H.-X., Tang, J., Li, R., & Ma, T. (2023) · BMC Neurology · doi:10.1186/s12883-023-03503-0 · Cited by 6
“C3 [6], complement receptor 1 (CR1) [7], C1q [8], and C3aR [6] are involved in Aβ metabolism.”
BackgroundHuuha, A. M., Norevik, C. S., Coombes, J. S., Røsbjørgen, R. N., Miguel‐dos‐Santos, R., Moreira, J. B. N., Kobro‐Flatmoen, A., Scrimgeour, N. R., & Tari, A. R. (2024) · Brain Plasticity · doi:10.3233/bpl-230154 · Cited by 5
“:3) clearance, depressed neurogenesis and promoted neurodegeneration [4, 7–9].”
BackgroundNeuroimmune Dysfunction in Alzheimer’s Disease and Other Forms of Dementia
Yamane, T., Yoshioka, T., & Shimo, Y. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00464 · Cited by 5
Ban, F., Zhou, L., Yang, Z., Liu, Y., & Zhang, Y. (2024) · Marine Drugs · doi:10.3390/md22070324 · Cited by 5
“…immune signaling may not only be the result of protein aggregation in the CNS but may lead to the accumulation of aggregates at the early stages of the disease process [2–4]; in particular, growing immune-related genetic mutations have been suggested to be risk factors for neurodegeneration [5].”
BackgroundLi, H., Terrando, N., & Gelbard, H. A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_24 · Cited by 4
Lázaro, S. P., Barrio, T., Bravo, S. B., Sevilla, E., Otero, A., Chantada‐Vázquez, M. D. P., Martín‐Burriel, I., Requena, J. R., Badiola, J. J., & Bolea, R. (2024) · Veterinary Quarterly · doi:10.1080/01652176.2024.2424837 · Cited by 4
The role of astrocytes in Alzheimer’s disease: a bibliometric analysis
An, X., He, J., Bi, B., Wu, G., Xu, J., Yu, W., & Ren, Z. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1481748 · Cited by 5
Cheng, J., He, Y., Wang, Z., Wang, Z., Peng, X., & Zhang, L. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70311 · Cited by 4
Diverse cell types establish a pathogenic immune environment in peripheral neuropathy
Choi, J. Y., Strickland, A. M., Loo, H. Q., Dong, W., Barbar, L., Bloom, A. J., Sasaki, Y., Jin, S. C., DiAntonio, A., & Milbrandt, J. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03459-7 · Cited by 6
“In AD models, complement and microglia mediate early synapse loss, highlighting the potential detrimental effect of complement activation in SARM1-dependent neuropathy [90].”
A good sleep for a fresh mind in patients with acute traumatic brain injury
Soddu, A., & Bassetti, C. L. (2016) · Neurology · doi:10.1212/wnl.0000000000003529 · Cited by 4
The THIK and Thin of Microglia Dynamics
Shih, J., & Dulla, C. G. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.002 · Cited by 4
Emerging Mechanisms in Alzheimer’s Disease and Their Therapeutic Implications
Strittmatter, S. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.002 · Cited by 4
“In part, Aβ may exert synaptotoxic actions indirectly through microglia and complement (12).”
BackgroundPassive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
“Interestingly, an anti-C1q antibody rescued Aβ-induced synaptotoxicity in vivo, and LTP impairment in situ, when compared to isotype control [99].”
Hua, J., Wei, X., Bian, Y., Ma, X., Li, H., Sun, J., Fan, J., Niu, Y., & Wang, Y. (2022) · CrystEngComm · doi:10.1039/d2ce00215a · Cited by 4
Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic
Logiacco, F., Grzegorzek, L. C., Cordell, E., Popp, O., Mertins, P., Gutmann, D. H., Kettenmann, H., & Semtner, M. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01525-w · Cited by 4
“In the early stages of Alzheimer’s disease, microglia facilitate the destruction of neuronal networks due to their ability to prune synapses [29, 29, 30, 30, 34], whereas the loss of phagocytic and surveillance activity contributes to enhanced Aß plaque burden at later stages [35, 67].”
BackgroundWilliams, E., Mutlu-Smith, M., Alex, A., Chin, X. W., Spires‐Jones, T. L., & Wang, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221185 · Cited by 6
Li, C., Liu, K., Zhu, J., & Zhu, F. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00366-4 · Cited by 7
“In addition, complement and microglia mediate the early loss of synapses in AD mouse models [17].”
BackgroundSummary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
He, D., Chen, J., Du, X., & Xu, L. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1222626 · Cited by 5
“These high cytokine levels produced by microglia can aggravate neuronal axon and synaptic damage, impairing the integrity of white matter across multiple brain regions (Hong et al., 2016).”
Proteomic Analysis Reveals Potential Exosomal Biomarkers in Patients With Sporadic Alzheimer Disease
Plaschke, K., Kopitz, J., Gebert, J. F., Wolf, N. D., & Wolf, R. C. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000589 · Cited by 4
“20 The role of exosomes in the process of complement pathway activation, however, is unknown.”
BackgroundBortolin, V., Mansuroglu, Z., Conquet, L., Calcagno, G., Lambert, F., Marin‐Obando, J. P., Segrt, H., Savino, M., Menidjel, R., Souès, S., et al. (2024) · Glia · doi:10.1002/glia.24619 · Cited by 4
Cai, J., Rong, H., Chen, J., Deng, Z., Chen, S., Liao, H., Pan, D., Chen, Y., Shi, Z., Li, Y., et al. (2024) · Age and Ageing · doi:10.1093/ageing/afae274 · Cited by 4
Aging, Dementia, and Alzheimer Disease
Sontheimer, H. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800244-5.00004-5 · Cited by 8
IMMUNOLOGY THEORY OF ALZHEIMER DISEASE PATHOGENESIS: FACTS AND HYPOTESIS
Zuev, V. A. (2019) · Современные проблемы науки и образования · doi:10.17513/spno.28961 · Cited by 4
Hassan, Z., & Sriramaneni, R. N. (2021) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v4i3.77 · Cited by 4
“In addition, the activated microglia also release pro-inflammatory cytokines, which can have direct excitotoxic effects on the synapses (Hong et al., 2016; Wang et al., 2015).”
BackgroundComplements to the Chef: Are Microglia Eating Neurons in the Epileptic Brain?
Koenig, J. B., & Dulla, C. G. (2018) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7597.18.2.128 · Cited by 5
Cannavo, C., Tosh, J., Fisher, E., & Wiseman, F. K. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.004 · Cited by 6
Arinuma, Y. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000810 · Cited by 4
“For example, a recent study in Alzheimer’s disease model mouse showed that C1q-binding on neuronal synapses was a critical step for recognition and activation of microglia leading to remodeling of neurons and that the binding of C1q can be mediated by b-amyloid as a linker connecting between a synapse and C1q in Alzhe…”
BackgroundResultLarrick, J. W., Alfenito, M. R., Scott, J. K., Parren, P. W. H. I., Burton, D. R., Bradbury, A. M., Lemere, C. A., Messer, A. C., Huston, J. S., Carter, P. J., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1227665 · Cited by 4
“She and her colleagues at Harvard Medical School have recently described striking results that implicate microglia and complement in early synapse loss in aging and AD.(19,20)”
ResultSelf-citationCserép, C., Pósfai, B., Orsolits, B., Molnár, G., Heindl, S., Lénárt, N., Fekete, R., László, Z. I., Lele, Z., Schwarcz, A. D., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3339900 · Cited by 4
Carlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V., Kitchen, R. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.230680 · Cited by 4
“C4A has been genetically and mechanistically implicated in synaptic dysfunction in both schizophrenia (Sekar et al., 2016) and AD (Hong et al., 2016; Zorzetto et al., 2016).”
BackgroundMaes, M. H. J., Vojdani, A., Sirivichayakul, S., Barbosa, D. S., & Kanchanatawan, B. (2020) · Preprints.org · doi:10.20944/preprints202012.0457.v1 · Cited by 3
Wu, X., Ji, M., Wang, R.-Z., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3940197 · Cited by 4
Luo, J., Huang, X., Li, R., Xie, J., Chen, L., Zou, C., Pei, Z., Mao, Y., & Zou, D. (2022) · medRxiv · doi:10.1101/2022.03.11.22272061 · Cited by 3
“Previous studies have shown that accumulation of pathological Aβ or Tau at the synapse can upregulate C1q in microglia and promote complement activation and subsequent microglia phagocytosis at the synapse (50-53).”
BackgroundRueda‐Carrasco, J., Sokolova, D., Lee, S., Childs, T., Jurčáková, N., Schepper, S. D., Ge, J. Z., Lachica, J., Toomey, C. E., Freeman, O. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.04.486424 · Cited by 4
Self-citationMondal, M., Solomon, S., Sun, J., Sampathkumar, N. K., Carre, I., Côtel, M.-C., Mehta, P. R., Rajendran, L., Vernon, A. C., Fang, F., et al. (2023) · medRxiv · doi:10.1101/2023.11.10.23298358 · Cited by 4
“Reactivation of this developmental process likely contributes to the cognitive decline occuring in AD as a consequence of synapse loss ( Rajendran and Paolicelli, 2018 , Hong et al., 2016 ) .”
BackgroundZhang, Y., Watson, B. R., Rattan, A., Lee, T., Chawla, S., Geistlinger, L., Guan, Y., Ma, M., Caldarone, B. J., Song, W., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.22.568325 · Cited by 4
Johnston, K. G., Berackey, B. T., Tran, K. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3656139/v1 · Cited by 4
“…neurites[13], regulation of development and spread of Tau pathology[14], destruction of perineuronal nets[15, 16], and synaptic and neuronal loss[15, 17–20], though the role of microglia in suppressing or aggravating impacts of AD is currently unclear, and may vary with disease progression[21].”
BackgroundLai, A. Y., Almanza, D. L., Ribeiro, J. A., Hill, M. E., Mandrozos, M., Koletar, M. M., Stefanovic, B., & McLaurin, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.11.575200 · Cited by 5
Vivi, E., & Benedetto, B. D. (2024) · Preprints.org · doi:10.20944/preprints202311.0117.v2 · Cited by 4
Wang, Y., Wu, T. Z., Gogineni, A., Tsai, M., Kielpinski, L. J., Mahajan, A., Pandey, S., Schachner, L. F., Tran, J. C., Wu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.609240 · Cited by 5
Glia multitask to compensate for neighboring glial cell dysfunctionPreprint
Beachum, A. N., Salazar, G., Nachbar, A., Krause, K., Klose, H., Meyer, K., Maserejian, A., Ross, G., Boyd, H., Weigel, T. K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.06.611719 · Cited by 4
Cell type transcriptomics reveal shared genetic mechanisms in Alzheimer’s and Parkinson’s diseasePreprint
Bhattacharya, A., Fon, E. A., Dagher, A., Iturria‐Medina, Y., Stratton, J. A., Savignac, C., Stanley, J., Hodgson, L. M., Hammou, B. A., Bennett, D. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.17.638647 · Cited by 4
Wu, J., Chen, X., Zhang, J., Wettschurack, K. W., Robinson, M. J., Li, W., Zhao, Y., Yoo, Y.-E., Deming, B. A., Abeyaratna, A. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.04.657874 · Cited by 5
CD33-CD45 Interaction Reveals a Mechanistic Link to Alzheimer’s Disease SusceptibilityPreprint
Vo, N., Rillahan, C. D., Chatila, Z. K., Virga, D. M., Hall, J. L., Tamucci, K. A., Rashid, M., Connor, S. M., Chintamen, S., Guzman, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.28.667311 · Cited by 5
Mechanobiological Specialization of Choroid Plexus Macrophages Defined by Titin ExpressionPreprint
Bhatta, S., Grzybowski, A., Ortiz, G., & DiStasio, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700716 · Cited by 5
“While microglial activation in the parenchyma has been extensively studied 15 , 14 , the choroid plexus (ChP) represents an overlooked interface where peripheral immune cells interact with CNS-derived signals 1 , 16 , 17 .”
A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions
Aboelnour, E. L., Vanoverbeke, V. R., Maupin, E. A., Hatfield, M. M., & Adams, K. L. (2026) · Nature Communications · doi:10.1038/s41467-026-72383-y · Cited by 7
Mansour, H. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102195 · Cited by 3
Wang, Y., Zhou, Y., Wang, S., Liu, L., Jiang, L. H., Zhang, Y., Zhang, L., Zhou, C., Luo, Y., Tang, J., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.010 · Cited by 5
The associations of cerebrospinal fluid ApoE and C1q with Alzheimer's disease biomarkers
Lin, Y.-J., Liu, Y., Sheng, Z.-H., Fu, Y., Ma, L.-Z., Zhang, Z.-H., Wang, L.-Y., Huang, L.-Y., Liu, M., Wang, Z.-T., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251320419 · Cited by 3
“34 Increased C1q leads to an increase in the complement protein C3.”
Wu, F., Dallaire‐Théroux, C., Michaud, É., Bergeron, F., Lavoie, M., Soucy, J., Dirani, A., & Laforce, R. J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331231 · Cited by 3
“91 Linking mechanisms to fi ndings.”
Yin, T., Sun, S., Peng, L., Yang, M., Li, M., Yang, X., Yuan, F., Zhu, H., & Wang, S. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02202-2 · Cited by 3
“Microglia are known to interact with neurons [37, 38], facilitating the reshape of neural circuit patterns through synaptic pruning over extended periods [39].”
Yu, K., Jiang, R., Zhou, D., & Zhao, Z. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251344572 · Cited by 4
“36 CR1 has emerged as a potential risk factor for neuroin fl ammation.”
Düsedau, H. P., Cangalaya, C., Stoyanov, S., Dityatev, A. E., & Dunay, I. R. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1616390 · Cited by 4
“This is further supported by the observation of a re-activated excessive pruning of viable synapses by aberrantly and irregularly activated microglia during neuroinflammatory conditions (Hong et al., 2016; Vasek et al., 2016).”
Wang, Z., Zhang, Z., Shi, J., & Zhao, R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05192-x · Cited by 4
“The study on microglial phagocytosis suggests that inhibiting complement-related pathways or receptors reduces both the number of phagocytic microglia and the extent of early synaptic loss [58].”
Tripathi, A., Bartosh, A., Jose, D. A., Mata, J., Hussein, U. K., Laezza, F., Zhao, Z., & Pillai, A. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03097-8 · Cited by 5
“…focused on the immune regulatory functions of complement system recent studies indicate their roles in phagocytosis of synaptic molecules in the CNS. Speci fi cally, synaptic stripping of neuronal connections has been demonstrated to occur via a complement-dependent mechanism [29, 32, 47 – 51].”
Wang, B., Wang, Z., Lv, L., Wang, X., Lu, J., Zhao, Y., Jiang, R., Li, Q., Kong, Y., Yang, X., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70633 · Cited by 4
“39,40 To evalu-atetheimpactofTn-Rknockdownonmicroglialactivationsurrounding A β plaques,weperformedimmunofluorescencestainingusingantibod-ies against A β and Iba-1, with Iba-1 serving as a specific marker for microglia.”
Self-citation
Metadata
- Authors
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Beja-Glasser, Victoria F.
- Nfonoyim, Bianca M.
- Stevens, Beth
- ORCID
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 712-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5094372
- OpenAlex
- W2314634699
- Cited by
- 3,343
- References
- 33
- Citations by year
- 2026: 415 · 2025: 391 · 2024: 384 · 2023: 388 · 2022: 324 · 2021: 363 · 2020: 306 · 2019: 260 · 2018: 240 · 2017: 198 · 2016: 69
- FWCI
- 140.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Edward R. and Anne G. Lefler Fellowship
- Coins for Alzheimer's Research Trust
- Fidelity Biosciences Research Initiative
- JPB Foundation
- National Institutes of Health (AG000222)
- National Institute of Neurological Disorders and Stroke-NIH (R01NS083845)
- National Institute on Aging-NIH (1RF1AG051496A)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, synaptic loss, complement system, microglia, C1q, CR3, complement C3, soluble amyloid-beta oligomers, neuroinflammation, synaptic pruning, hippocampal long-term potentiation, phagocytosis, mouse model
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Cognition Disorders, Complement Pathway, Classical, Disease Models, Animal, Membrane Proteins, Phagocytosis, Synapses, Up-Regulation, Complement C1q, Macrophage-1 Antigen, Amyloid beta-Peptides, Synaptophysin, Microglia, Long-Term Potentiation, Mice, Knockout, Mice, Guanylate Kinases, CA1 Region, Hippocampal, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.